Company profile
INTELLIA THERAPEUTICS, INC.
NASDAQ:NTLABiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LONVOGURAN | phase3 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06672237 | phase3 | recruiting | 2024-11-22 | 2027-07-01 | Intellia Therapeutics | A Phase 3 Study of NTLA-2001 in ATTRv-PN |
| NCT06634420 | phase3 | active_not_recruiting | 2025-01-15 | 2026-02-10 | Intellia Therapeutics | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) |
| NCT06128629 | phase3 | recruiting | 2023-12-13 | 2027-12-01 | Intellia Therapeutics | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) |
| NCT05120830 | phase1_2 | active_not_recruiting | 2021-12-10 | 2024-04-04 | Intellia Therapeutics | NTLA-2002 in Adults With Hereditary Angioedema (HAE) |
| NCT06622668 | phase1_2 | withdrawn | 2024-11-20 | 2025-01-09 | Intellia Therapeutics | NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease |
FDA applications (0)
No records yet.